CareDx, Inc. (CDNA) stock
CDNANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 12/3023% above fair value
$79.81−1.36 (-1.68%)
Close on Nov 12, 2026Market cap $4.19BP/E 33.4Yield –
CareDx EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
CareDx's EPS for the twelve months ending Sep 30, 2026 was $2.39. For fiscal 2025 it was -$0.40, down 143.0% from the year before. The highest annual figure on record is $0.93 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.40 | -143.0% |
| FY2024 | Dec 31, 2024 | $0.93 | – |
| FY2023 | Dec 31, 2023 | -$3.54 | – |
| FY2022 | Dec 31, 2022 | -$1.44 | – |
| FY2021 | Dec 31, 2021 | -$0.59 | – |
| FY2020 | Dec 31, 2020 | -$0.40 | – |
| FY2019 | Dec 31, 2019 | -$0.52 | – |
| FY2018 | Dec 31, 2018 | -$1.31 | – |
| FY2017 | Dec 31, 2017 | -$2.38 | – |
| FY2016 | Dec 31, 2016 | -$2.39 | – |
| FY2015 | Dec 31, 2015 | -$1.16 | -1260.0% |
| FY2014 | Dec 31, 2014 | $0.10 | – |
| FY2013 | Dec 31, 2013 | -$3.50 | – |
| FY2012 | Dec 31, 2012 | -$5.01 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.35 | +1066.7% |
| Q2 FY2026 | Jun 30, 2026 | $2.07 | – |
| Q1 FY2026 | Mar 31, 2026 | $0.05 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.08 | – |
| Q3 FY2025 | Sep 30, 2025 | $0.03 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.16 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.19 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.20 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.09 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.38 | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.21 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.43 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.46 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.44 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.34 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.32 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.41 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.37 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.31 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.23 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.04 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.01 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.07 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.06 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.15 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.14 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.11 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.04 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.19 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.18 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.09 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.54 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.40 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.30 | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.13 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.63 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.19 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.26 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.73 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?